Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 5/20 | 0.49 |
| ▸ | CRHBP | P24387 | 2/20 | 0.47 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.46 |
| ▸ | CASR | P41180 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6789874 | 1.00 | EPHX1 (0.49) | EPHX1CRHBPCRHR2SLC6A3CASR | |
| SCHEMBL6380441 | 0.83 | TSHR (0.56) | EPHX1SLC6A3ALDH1A1CNR1MEN1 | |
| SCHEMBL5727321 | 0.83 | EPHX1 (0.53) | EPHX1SLC6A3CASRCNR1 | |
| SCHEMBL5726563 | 0.83 | EPHX1 (0.53) | EPHX1SLC6A3CASRCNR1 | |
| SCHEMBL5727545 | 0.83 | EPHX1 (0.53) | EPHX1SLC6A3CASRCNR1 | |
| SCHEMBL6380819 | 0.81 | EPHX1 (0.67) | EPHX1SLC6A3CASRCNR1MEN1 | |
| SCHEMBL31357785 | 0.77 | CRHBP (0.55) | CRHBPCRHR2ALDH1A1HTTMEN1 | |
| SCHEMBL6382165 | 0.76 | MAPT (0.62) | CNR1HTTMEN1KMT2AGAA | |
| SCHEMBL261231 | 0.76 | KIF11 (0.54) | CRHBPCRHR2ALDH1A1HTTGAA | |
| SCHEMBL10802920 | 0.76 | CNR1 (0.63) | ALDH1A1CNR1HTTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040235919-A1 | Phenylacetamido-thiazole derivatives, process for the preparation and their use as antitumor agents | PFIZER ITALIA S.R.I. (IT) | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235919-A1 | Phenylacetamido-thiazole derivatives, process for the preparation and their use as antitumor agents | CDK2, CDK1, CDKN1A | EPHX1 3644/4885CRHBP 4741/4885CRHR2 4621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.